Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab

Blood

Volumn 112, Issue 3, 2008, Pages 830-835

  Gopal, Ajay K ^a,b   Press, Oliver W ^a,b   Wilbur, Shani M ^b   Maloney, David G ^a,b   Pagel, John M ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD45 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D8; MONOCLONAL ANTIBODY BC8; MONOCLONAL ANTIBODY BC8 I 125; MONOCLONAL ANTIBODY HB8181; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; RADIOACTIVE IODINE; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; B CELL LYMPHOMA; CANCER CONTROL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; XENOGRAFT; ANIMAL; DRUG INTERACTION; DRUG SCREENING; IMMUNOLOGY; METHODOLOGY; NUDE MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD45; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOCONJUGATES; IODINE RADIOISOTOPES; LYMPHOMA, B-CELL; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 50949103161     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-132142     Document Type: Article

References (23)

1. Kaminski MS, Tuck M, Estes J, et al. 1311-tositumomab therapy as initial treatment for follicularlymphoma. N Engl J Med. 2005;352:441-449.
2. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270.
3. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against nonHodgkin lymphomas. Blood. 2004;104:1793-1800.
4. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
5. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-2195.
6. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
7. Maloney DG. Follicular NHL: From antibodies and vaccines to graft-versus-lymphoma effects. Hematology Am Soc Hematol Educ Program. 2007;226-232.
8. Mangel J, Buckstein R, lmrie K, et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy after autologous stem cell transplantation. Ann Oncol. 2003;14:758-765.
9. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295-3301.
10. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003-4008.
11. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase Il trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1088-1095.
12. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23:712-719.
13. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibhtumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular nonHodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
14. Matthews DC, Martin PJ, Nourigat C, Appelbaum FR, Fisher DR, Bernstein ID. Marrow ablative and immunosuppressive effects of 131 I-anti-CD45 antibody in congenie and H2-mismatched murine transplant models. Blood. 1999;93:737-745.
15. Press OW, Corcoran M, Subbiah K, et al. Acornparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
16. Reddy N, Ong GL, Behr,TM, Sharkey RM, Goldenberg DM, Mattes MJ. Rapid blood clearance of mouse lgG2a and human IgG1 in many nude and nu/+ mouse strains is due to low IgG2a serum concentrations. Cancer Immunol lmmunother. 1998;46:25-33.
17. Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131 l]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stemcell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 2007;25:1396-1402.
18. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131 I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459-465.
19. Press OW, Eary JF,Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224.
20. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
21. Knowles DA. Neoplastic Hematopathology. 2nd ed. New York, NY: Lippincott Williams & Wilkins; 2001.
22. Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107:2184-2191.
23. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177:362-371.